Chimeric Therapeutics (ASX:CHM) Advances in Trial: GMP Manufacturing Complete, Shares Up 11%

August 16, 2024 11:09 AM AEST | By Sonal Goyal

Chimeric Therapeutics (ASX:CHM) Advances in Trial: GMP Manufacturing Complete, Shares Up 11% — Image source: Company update

Recent News

Planet Image International Limited Reports the First Half of Fiscal Ye...

Recognizing Excellence: Covia Receives NIOSH Mine Safety and Health Te...

This German chip stock is a Best Idea for the Q4 at Bernstein

Vision China: US, China urged to find right path in ties

Highlights

Good Manufacturing Practice (GMP) manufacturing has been completed, enabling treatment of the first patient in the Phase 1/2 CHM CDH17 CAR-T trial.

Additional clinical sites are expected to open in the second half of 2024.

CHM shares surged by 11% following the update.

Shares of Chimeric Therapeutics Limited (ASX:CHM) jumped over 11% during early morning trading on 16 August 2024, reaching AU$0.019 apiece. This uptick followed the company’s announcement of progress in its Phase 1/2 CHM CDH17 CAR-T trial. GMP manufacturing has been completed, paving the way for the treatment of the first participant in the trial.

The cells of the clinical trial participant were collected at the Sarah Cannon Cancer Centre in Nashville, and then sent to the contract manufacturing facility. Following GMP manufacturing, the CHM CDH17 CAR-T cells successfully passed specification testing and quality assurance review. They are in transit to the clinical trial site for infusion.

Details of the Phase 1/2 CHM CDH17 CAR-T trial

The Phase 1/2 clinical trial is designed to determine the recommended Phase 2 dose of the first-in-class, third generation CHM CDH17 CAR T. This two-stage study aims to assess both the safety and objective response rate in patients with advanced intestinal neuroendocrine tumours, as well as colorectal and gastric cancer.

The company plans to open additional clinical sites in the latter half of 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.